pre-update Archives

Publication

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…

Danielle Pillsbury2024 年 8 月 26 日

Article

The Uncertain Path Forward for Psychedelic Medicine

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

Danielle Pillsbury2024 年 8 月 26 日

Blog

Streamline your clinical trials with automated metadata management

When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…

Simona Colucci2024 年 8 月 26 日

Blog

Regulatory requirements for annotated CRFs made easy

aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for…

Simona Colucci2024 年 8 月 26 日

Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

Rajesh Krishna2024 年 8 月 23 日

Article

克服细胞和基因治疗中的 CMC 挑战：第 I 部分

In this Manufacturing Chemist article, Certara's Drs. Hien Anh Bruno and Deven Shah discuss the…

Danielle Pillsbury2024 年 8 月 23 日

Press Release

Certara 将参加即将举行的投资者会议

RADNOR, Pa. — 2024 年 8 月 21 日 -- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…

Danielle Pillsbury2024 年 8 月 21 日

Blog

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

Cytokine Release Syndrome Cytokine release syndrome (CRS) is an inflammatory immune reaction that clinically manifests…

Renee Fisher2024 年 8 月 20 日

On-Demand Webinar

驾驭新领域：Joint Advice on FDA/EMA Compliance – Aligning with Evolving EU Regulations

Presentation Materials

Danielle Pillsbury2024 年 8 月 20 日

On-Demand Webinar

驾驭新领域：不断演变的欧盟法规对监管事务的影响

Presentation Materials Don't miss Part 2 in the series Joint Advice on FDA/EMA Compliance…

Danielle Pillsbury2024 年 8 月 20 日

pre-update

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The Uncertain Path Forward for Psychedelic Medicine

Streamline your clinical trials with automated metadata management

Regulatory requirements for annotated CRFs made easy

Resmetirom: A pioneering NASH clinical program

克服细胞和基因治疗中的 CMC 挑战：第 I 部分

Certara 将参加即将举行的投资者会议

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

驾驭新领域：Joint Advice on FDA/EMA Compliance – Aligning with Evolving EU Regulations

驾驭新领域：不断演变的欧盟法规对监管事务的影响

订阅时事通讯

快捷链接

解决方案

联系我们